Prolensa®
Bromfenac 0.07% · ophthalmic solution
NSAID
Approved uses
Postoperative inflammation and ocular pain after cataract surgery
One drop QD to the affected eye starting 1 day before surgery, on the day of surgery, and through the first 14 days postoperatively.
Anterior chamber cells reach zero-to-trace in 80% by day 15, with separation from placebo by day 3.
Contraindications
None listed on the FDA label.
0.07% ophthalmic solution, 3 mL in a 7.5 mL dropper bottle
Nonsteroidal anti-inflammatory drug; its action is thought to be due to its ability to block prostaglandin synthesis by inhibiting cyclooxygenase (COX) 1 and 2. Prostaglandins have been shown in many animal models to be mediators of certain kinds of intraocular inflammation. In studies performed in animal eyes, prostaglandins have been shown to produce disruption of the blood-aqueous humor barrier, vasodilation, increased vascular permeability, leukocytosis, and increased intraocular pressure.
Warnings & Precautions
- Keratitis and corneal reactions: Topical NSAIDs may cause keratitis, and in some susceptible patients continued use may result in epithelial breakdown, corneal thinning, corneal erosion, corneal ulceration, or corneal perforation, any of which may be sight threatening. Discontinue immediately on evidence of corneal epithelial breakdown and monitor corneal health closely.
- Corneal adverse events: Postmarketing experience with topical NSAIDs suggests that patients with complicated ocular surgeries, corneal denervation, corneal epithelial defects, diabetes mellitus, ocular surface diseases (e.g., dry eye syndrome), rheumatoid arthritis, or repeat ocular surgeries within a short period of time may be at increased risk for corneal adverse events, which may become sight threatening; use with caution in these patients.
- Corneal adverse events with timing of use: Postmarketing experience with topical NSAIDs also suggests that use more than 24 hours prior to surgery or use beyond 14 days postsurgery may increase patient risk for the occurrence and severity of corneal adverse events.
- Sulfite allergic reactions: Contains sodium sulfite, which may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people; sulfite sensitivity is seen more frequently in asthmatic than in non-asthmatic people.
- Slow or delayed healing: All topical NSAIDs may slow or delay healing, as do topical corticosteroids, and concomitant use may increase the potential for healing problems.
- Cross-sensitivity: Potential cross-sensitivity to acetylsalicylic acid, phenylacetic acid derivatives, and other NSAIDs; use caution in patients who have previously reacted to these drugs.
- Increased bleeding time: With some NSAIDs, including bromfenac, there exists the potential for increased bleeding time due to interference with platelet aggregation, and there have been reports that ocularly applied NSAIDs may cause increased bleeding of ocular tissues (including hyphemas) in conjunction with ocular surgery. Use caution in patients with known bleeding tendencies or who are receiving other medications which may prolong bleeding time.
- Risk of contamination: Do not touch dropper tip to the eye, eyelids, or to any surface, as this may contaminate the contents. Replace the bottle cap after using.
- Contact lens wear: Not to be instilled while wearing contact lenses. Remove contact lenses prior to instillation; the preservative, benzalkonium chloride, may be absorbed by soft contact lenses. Lenses may be reinserted after 10 minutes following administration.
Common Side Effects
Ocular, 3% to 8%: Anterior chamber inflammation, foreign body sensation, eye pain, photophobia, blurred vision.
Pregnancy: No data in pregnant women. Systemic exposure after topical ocular dosing is expected to be minimal, but avoid use in late pregnancy because prostaglandin synthesis inhibitors can close the fetal ductus arteriosus. Oral dosing through organogenesis produced embryo-fetal lethality and maternal toxicity in rats and rabbits at 90 and 150 times the predicted human Cmax at the recommended ophthalmic dose; rats also showed delayed parturition at 30 times and dystocia, increased neonatal mortality, and reduced postnatal growth at 90 times.
Lactation: No data on presence in human milk, effects on the breastfed infant, or effects on milk production; systemic exposure from ocular dosing is expected to be minimal, though harm to the infant cannot be ruled out.
Safety and effectiveness not established in pediatric patients.